Skip to main content
Journal ArticleOPEN ACCESS

Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential

  • Duvic M
  • Evans M
  • Wang C
Therapeutic Advances in Hematology (2016) 7(3) 171-174
DOI: 10.1177/2040620716636541
N/ACitations
Citations of this article
54Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.

Cite

CITATION STYLE

APA

Duvic, M., Evans, M., & Wang, C. (2016). Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Therapeutic Advances in Hematology, 7(3), 171–174. https://doi.org/10.1177/2040620716636541

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free